Relationship of PCNA, C-erbB2 and CD44s expression with tumor grade and stage in urothelial carcinomas of the bladder.

In the present study, the intention was to reveal the relationship of histological grade and stage with c-erbB2, CD44s, and PCNA immunoreactivity in bladder urothelial carcinomas (UC). In our study, we evaluated 46 items of transurethral resection material of patients submitted by YYU Faculty of Medicine, Main Department of Pathology, with a mass revealed in their bladder after clinical and radiological studies at our laboratories and who were diagnosed with urothelial carcinomas. PCNA, c-erbB2, and CD44s were applied in an immunohistochemical manner comprised from nine low-malignant potential papillary urothelial neoplasia, 23 low-grade papillary urothelial carcinoma, and 14 high-grade papillary urothelial carcinoma. Immunostaining was scored according to the percentage of positive cells. The immunohistochemical study demonstrated that the c-erbB2 and PCNA staining ratio increased when an increase occurred in stage and grade. The CD44s staining ratio decreased. C-erbB2, PCNA, and CD44s appear to be a useful marker in the assessment of the prognosis and treatment options in urothelial carcinomas.

[1]  T. Yamamoto,et al.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.

[2]  Lawrence D. True,et al.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder , 1998 .

[3]  D. Neal,et al.  C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. , 1996, The Journal of urology.

[4]  H. Akaza,et al.  Proliferating cell nuclear antigen cyclin in human transitional cell carcinoma. , 1995, British journal of urology.

[5]  T. Sugino,et al.  Progressive loss of CD44 gene expression in invasive bladder cancer. , 1996, The American journal of pathology.

[6]  R. Mansel,et al.  The role of the CD44/ezrin complex in cancer metastasis. , 2003, Critical reviews in oncology/hematology.

[7]  F. Pierconti,et al.  HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3). , 2013, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

[8]  V. Kosma,et al.  Expression of CD44 standard and variant‐v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long‐term follow‐up , 1998, The Journal of pathology.

[9]  J W Arends,et al.  A simplified grading method of transitional cell carcinoma of the urinary bladder: reproducibility, clinical significance and comparison with other prognostic parameters. , 1994, British journal of urology.

[10]  J. Figge,et al.  Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[11]  J. McKenney,et al.  Relationship of Cytokeratin 20 and CD44 Protein Expression with WHO/ISUP Grade in pTa and pT1 Papillary Urothelial Neoplasia , 2000, Modern Pathology.

[12]  A. Elhan,et al.  The prognostic value of proliferating cell nuclear antigen, Ki-67 and nucleolar organizer region in transitional cell carcinoma of the bladder , 2004, International Urology and Nephrology.

[13]  K. Kihara,et al.  Late Recurrence and Progression after a Long Tumor-Free Period in Primary Ta and T1 Bladder Cancer , 1999, European Urology.

[14]  David G. Bostwick,et al.  Urothelial papillary (exophytic) neoplasms , 2002, Virchows Archiv.

[15]  A. Feller,et al.  HER2 overexpression in muscle‐invasive urothelial carcinoma of the bladder: Prognostic implications , 2002, International journal of cancer.

[16]  I. Sesterhenn,et al.  World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .

[17]  P. Swanson,et al.  Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. , 1994, American journal of clinical pathology.

[18]  L. Beckett,et al.  Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? , 2002, Cancer.

[19]  O. Omran,et al.  CD44s and CD44v6 in Diagnosis and Prognosis of Human Bladder Cancer , 2012, Ultrastructural pathology.

[20]  L. David,et al.  c-erb B-2 Expression Is Associated with Tumor Location and Venous Invasion and Influences Survival of Patients with Gastric Carcinoma , 2002, International journal of surgical pathology.

[21]  Y. Pu,et al.  Expressions of E-cadherin and exon v6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma. , 1995, The Journal of urology.

[22]  G. Sauter,et al.  Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma. , 1999, The American journal of pathology.

[23]  P. Lipponen.  Interrelationship between expression of p53, proliferating cell nuclear antigen and c-erbB-2 in bladder cancer. , 1993, Pathobiology (Basel).

[24]  J. Bartlett,et al.  C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? , 1995, Cancer research.

[25]  M. Janssen-Heijnen,et al.  Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems , 2002, Journal of clinical pathology.

[26]  W. Gullick,et al.  c‐erbB‐2 oncoprotein expression in primary human tumors , 1990, Cancer.

[27]  J. McKenney,et al.  Discriminatory Immunohistochemical Staining of Urothelial Carcinoma in Situ and Non-neoplastic Urothelium: An Analysis of Cytokeratin 20, p53, and CD44 Antigens , 2001, The American journal of surgical pathology.

[28]  G. Ekuklu,et al.  Expression of the cyclin-dependent kinase inhibitor p27 in transitional cell bladder cancers: Is it a good predictor for tumor behavior? , 2004, International Urology and Nephrology.

[29]  Yosef Yarden,et al.  Biology of HER2 and Its Importance in Breast Cancer , 2001, Oncology.